Pathogen Inactivated Transfusion Plasma: Existing and Emerging Methods
2002; Wiley; Volume: 83; Issue: s1 Linguagem: Inglês
10.1111/j.1423-0410.2002.tb05347.x
ISSN1423-0410
Autores Tópico(s)Blood groups and transfusion
ResumoVox SanguinisVolume 83, Issue s1 p. 429-436 Pathogen Inactivated Transfusion Plasma: Existing and Emerging Methods Bernard Horowitz Ph.D., Corresponding Author Bernard Horowitz Ph.D. Horowitz Consultants, New Rochelle, NY, USABernard Horowita, Ph.D. Horowitz Consultants. New Rochelle. NY. USA E-mail. [email protected]@aol.comSearch for more papers by this author Bernard Horowitz Ph.D., Corresponding Author Bernard Horowitz Ph.D. Horowitz Consultants, New Rochelle, NY, USABernard Horowita, Ph.D. Horowitz Consultants. New Rochelle. NY. USA E-mail. [email protected]@aol.comSearch for more papers by this author First published: 11 February 2011 https://doi.org/10.1111/j.1423-0410.2002.tb05347.xCitations: 14Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Cohen H.. Avoiding the misuse of fresh frozen plasma. Br Med J 1993; 307: 395—6. 2 Lundberg GD. Practice parameters for the use of fresh frozen plasma, cryoprecipitate and platelets JAMA 1994; 271: 777—781. 3 World Health Organization Blood Transfusion Safety. The clinical use of blood. 2001. 4 Humpe A., Legler TJ. Nubling CM, Riggert J., Unger G., Wolf C., Heermann K-H, Kohler M.. Hepatitis C virus transmission through quarantine fresh-frozen plasma. Thromb Haemost 2000; 84: 784—8. 5 Araujo FM, Hennques I., Monteiro F. et al., The first case of HCV seroconversion in Portugal after the introduction of HCV NAT screening. Transfusion 2001, 41: 848—9. 6 Test misses HIV in blood given to Texan. New York Times. February 10, 2002. 7 Horowitz B., Bonomo R., Prince AM, Chin SN, Brotman B., Shulman RW, Solvent/detergent-treated plasma: A virus inactivated substitute for fresh frozen plasma. Blood 1992; 79: 826—831. 8 Piquet Y., Janvier G., Selosse P., Doutremepuich C., Jouneau J., Nicolle G., Platel D., Vezon G.. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results Vox Sang 1992; 63: 251—6. 9 Hellstem P., Sachse H., Schwinn H., Oberfrank K.. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992; 63: 178—185. 10 Leebeek FWG, Schipperus MR, van Vhet HHDM. Coagulation factor levels in solvent/detergent-treated plasma. Transfusion 1999; 39: 1150—1. 11 Inhal A., Epstein O., Blickstein D., Kornbrot N., Brenner B., Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagulation and Fibrinolysis. 1993; 4: 599—604. 12 Horowitz MS, Pehta JC SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74 Suppl 1: 231—235. 13 Williamson LM, Llewelyn CA, Fisher NC, Allain JP, et al. A randomized trial of solvent/detergent-treated and standard fresh- frozen plasma in the coagulopathy of liver disease and liver transplantation Transfusion 1999; 39 1227—34. 14 Lerner RG, Nelson J., Sorcia E., Grima K., Kancherla RR, Zarou-Naimo CM, Pehta JC. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000, 79: 161—7. 15 Haubelt H., Blome M., Kiessling AH, Isgro F., Bach J., Saggau W., Hellstern P.. Effects of solvent/detergent-treated plasma and fresh frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002; 82: 9—14. 16 Moake J., Chintagumpala M., Turner N., McPherson P., Nolasco L., Steuber C., Santiago-Borrero P., Horowitz M., Pehta P.. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84: 490—497. 17 Harrison CN, Lawrie AS, Inbal A. et al., Plasma exchange with solvent/detergent plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94: 756—8. 18 McCarthy L., Danielson C., Skipworth E., Fernandez C., Waxman D., Miraglia C.. Am Soc Apheresis. 2000. 19 Wallis C., Melnick JL. Photodynamic inactivation of animal viruses, a review Photochem Photobiol 1965; 4: 159–170. 20 Specht K.. The role of DNA damage in PM2 viral inactivation by methylene blue photosensitization. Photochem Photobiol 1994, 59: 506—514. 21 Abe H., Wagner SJ. Analysis of viral DNA, protein and envelope damage after methylene blue, phthalocyamne denvative or merocyamne 540 photosensitization. Phototochem Photobiol 1995, 61: 402—409. 22 Lambrecht B., Mohr H., Kn?ver-Hopf J., Schmitt H.. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light Vox Sang 1991; 60: 207—213. 23 AuBuchon JP, Pickard C., Herschel L., O'Conner JL, Lee E.. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang 1998, 74. 1—6. 24 Wagner SJ, Robinette D., Storry J., Chen XY, Shumaker J., Benade L.. Differential sensitivities of viruses in red cells suspensions to methylene blue photosensitization. Transfusion 1994; 34: 521—526. 25 Mohr H., Lambrecht B., Selz A.. Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24 73—85. 26 Knuever-Hopf J., Vogt I., Mohr H.. The influence of photodynamic treatment on the genome and the infectivity of parvovirus B19 Transfusion Clin Biol 2001; 8 Suppl I: 141. 27 Huhn D.. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994; 34: 685—689. 28 Aznar JA, Bonanad S., Montoro JM, Hurtado C., Cid AR, Soler MA DeMiguel A.. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupematants. Vox Sang 2000; 79: 156—160. 29 Wieding JU, Rathgeber J., Zenker D. Prospective, randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma Transfusion 1999; 39 Suppl S86-P Abs. 30 Hernandez JM, Castella D., Claparols M., Sauleda S., Masucl L. Clinical use of fresh frozen plasma virus inactivated with methylene blue Transfusion 1999, 39 Suppl: S94-P Abs. 31 Atance R., Pereira A., Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41. 1548—52. 32 Wieding JU, Neumeyer H. Erste Erfahrungen mit Methylenblau-virus inaktiviertem fresh-frozen-plasma Ergebnisse einer klinischen und an einer in vitro Studie Infusions therapie 1992, 19 84—90. 33 Mohr H., Kn?ver-Hopf J., Lambrecht B., Scheideckcr H., Schmitt H. No evidence for neoantigens in human plasma after photochemical virus inactivation Ann Hematol 1992; 65, 224—228. 34 Wagner SJ, Cifone MA, Murli H., Dodd RY, Myhr B.. Mammalian genotoxicity assessment of methylene blue in plasma implications for virus inactivation Transfusion 1995; 35 407—13. 35 Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound a clinical perspective. Sem Hematology 2001, 38 Suppl 11 12—19. 36 Alfonso R., Lin C., Dupuis K. et al, Inactivation of viruses with preservation of coagulation function in fresh frozen plasma. Blood 1996, 88 Suppl 1 2092 Abs. 37 Pinkoski L., Smyers J., Corash L., Ramies D., Wiesehahn G. Pathogen inactivation of plasma using Helinx technology conserves the activity of coagulation, anticoagulation and fibrinolytic proteins. Blood 2001, 98 2266 Abs. 38 Hillyer KL, Kelley VA, Roush S. et al, von Willebrand factor-cleaving protease activity in S-59-treated donor plasma. Blood 2001, 98 2256 Abs. 39 Alfonso R., Lin C., Dupuis K., Corten L., Reames A., Londe H., Chen C., Yip J., Cook D., Smyers J., Clarke S., Wages D., Naravan D., Hei D., Wiesenhahn G., Corash I. Inactivation of viruses with preservation of coagulation function in fresh frozen plasma. Blood 1996, 88 Suppl 1 2092 Abs. 40 Wages D., Smith D., Walsh J., Smyers J., Chen C., Moore C., Jue C., Davis K., Metzel P., Corash L., Cimino G., Hei D., Shafer S., Wiesenhahn G., Buchhol DH Virally inactivated fresh frozen plasma transfusion in normal volunteers Vox Sang 1998, 74 Suppl 1, 1290 Abs. 41 deAlarcon P., Benjamin R., Shopnick R., et al Hemostatic response in congenital coagulation factor-deficient patients transfused with Fresh Frozen Plasma (H.P) prepared by Helinx pathogen inactivation technology The step CC trial Transfusion 2001; 41 Suppl. SP-182 (Abs). 42 Burnouf-Radosevich M., Bumouf T., and Huart JJ A pasteurized therapeutic plasma. Infusionstherapie 1992, 19 91—94. 43 Goubran HA, Burnouf T., Radosevich M.. Virucidal heat-treatment of single plasma units a potential approach for developing countries Haemophilia 2000, 6 597—604. 44 Samar BM, Goodrich R.. Viral inactivation in plasma using riboflavin-based technology. Transfusion 2001. 41 Suppl SP178Abs (Note Some data was not in the published abstract but was provided on the poster). 45 Piper J., Murphy S., Schuyler R., Haynes R., Wilson A. Transfusion 2001, 41 Suppl SP186 Abs. 46 Hiemstra H., Tersmette M., Vos AHV, Over J., van Berkel MP, deBree H. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors Transfusion 1991, 31 32—9. 47 M McPhee, Clearant, Inc, Rockville, MD, USA Personal communication. 48 Rauth AM The physical state of viral nucleic acid and the sensitivity of viruses to ultraviolet light. Biophys J 1965, 5 257—273. 49 Kleim Thromb Haemost 1990; 64 336—337. 50 Finlayson J. et al. J Clin Invest 1960, 39 1837–1840, and Finlayson J et al J Clin Invest 1965; 44: 1561—1565. 51 Hart H., Reid K., Hart W. Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin Vox Sang 1993, 64 82—8. 52 Chin S., Williams B., Gottlieb P.. Margolis-Nunno H., Ben-Hur F., Hamman J., Jin R., Dubovi E., Horowitz B.. Virucidal UVC treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants Blood 1945, 86 4331—4336. 53 Chin S., Jin R., Wang XL, Hamman J., Marx G., Mou X., Andersson I., Lindquist LO, Horowitz B.. Virucidal treatment of blood protein products with UVC Photochem Photobiol 1997, 65 432—435. 54 http://www.purepulse.com. 55 Bradley DW, Hess RA, Tao F., Sciaba-Lentz L., Remaley AT, Laugham JA, Manak M.. Pressure cycling technology a novel approach to virus inactivation in plasma Transfusion 2000; 40: 193—200. 56 Edson CM, Hincapie M., Purmal A. Evaluation of Inactine as a second virucidal step for solvent detergent treated plasma. Transfusion 1999, 39 Suppl S85-P Abs. 57 Golitsina N., McKenzie A., Purmal A. Inactine PEN 110 mechanism of action disruption of nucleic acid replication Blood 2001; 98 4062 Abs. 58 ”Test misses H.I.V. in blood given to Texan NY Times February 10, 2002. 59 Public health dispatch Update Unexplained deaths following knee surgery Minnesota, 2001. MMWR Weekly 2001, 50 1080—1. 60 ABC Newsletter, March 15, 2002; 4–5. 61 Zeiler T., Riess H., Wittman G., Hintz G., Zimmermann R., Muller C., Heuft HG, Huhn D.. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single donor fresh-frozen plasma. Transfusion 1994; 34: 685—9. 62 Aznar JA, Bonanad S., Montoro JM, Hurtado C., Cid AR, Soler MA DeMiguel A.. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000; 79: 156—160. 63 Wieding JU, Hellstern P., Kohler M.. Inactivation of viruses in fresh-frozen plasma. Ann Hematol 1993; 67: 259—266. Citing Literature Volume83, Issues1August 2002Pages 429-436 ReferencesRelatedInformation
Referência(s)